Author: Opus Genetics, Inc.

Posted Date:

April 6, 2026

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital

Opus Genetics, Inc.

April 6, 2026
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

Opus Genetics, Inc.

March 24, 2026
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update

Opus Genetics, Inc.

March 10, 2026
Opus Genetics to Present at Upcoming Investor Conferences in March 2026

Opus Genetics, Inc.

March 3, 2026
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

Opus Genetics, Inc.

February 27, 2026
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

Opus Genetics, Inc.

February 25, 2026
Opus Genetics Announces $25 Million Private Placement

Opus Genetics, Inc.

February 13, 2026
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Opus Genetics, Inc.

February 2, 2026
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Opus Genetics, Inc.

January 28, 2026